Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUAL-HPV: Dual-Modality Immunotherapy for HPV Clearance
NCT07735039Active, not recruiting
- Sponsor
- Kartal Dr. Lütfi Kırdar City Hospital
- Start
- Apr 2026
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Randomised, single-blind trial in human papillomavirus infection (2 arms), sponsored by Kartal Dr. Lütfi Kırdar City Hospital. Primary endpoint: Human Papillomavirus clearance rate at 3 months. Started Apr 2026; status: active, not recruiting.
02
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT07735039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735039.